Increase in major osteoporotic fractures after therapy with immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) can cause severe and sometimes long-standing immune-related adverse events (irAEs). Enhanced immune activation from ICI can theoretically result in osteoclast activation, bone loss and fracture. The objective of this study was to evaluate the incidence rates of major osteoporotic fractures (MOFs) in patients with melanoma treated with ICI.

Methods

We conducted a before-after cohort study using a commercial healthcare claims dataset of adult patients with melanoma from the USA who received ICI therapy between 2011 and 2022. Incidence rates of MOF before and after ICI initiation were ascertained using International Classification of Diseases 9/10 diagnostic codes.

Results

The study cohort included 3137 patients, mean age wa

SUBMITTER: Ye C 

PROVIDER: S-EPMC11347678 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature